Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis and Moderate-to-Severe Psoriasis Receiving Secukinumab: A Retrospective Study / 대한피부과학회지

ABSTRACT

Background@#Psoriasis is a relapsing inflammatory skin disorder that can affect the nails and joints. Psoriatic arthritis (PsA) occurs in up to 30% of patients with psoriasis, leading to chronic articular pain, and impairing quality of life. Secukinumab is a human monoclonal antibody targeting interleukin-17A that has been shown to effectively improve the clinical signs and symptoms of PsA. @*Objective@#To evaluate the effect of secukinumab on health-related quality of life (HRQOL) in Korean PsA patients. @*Methods@#We retrospectively investigated the medical records and psoriasis area and severity index (PASI) scores of 13 patients with PsA who completed the psoriatic arthritis impact of disease 12-item questionnaire (PsAID-12) before and 3 months after receiving secukinumab treatment between October 2019 and August 2021 in Yeouido St.Mary’s Hospital. @*Results@#At week 12, significant reductions in the total and each item PsAID-12 and mean PASI score were observed (p＜0.01). The mean decrease of total PsAID-12 score was 4.8 (95% confidence interval [CI], 3.74∼5.86), with the greatest improvement observed in the item of ‘embarrassment’ (7.15; 95% CI, 5.59∼8.72). Of the 13 patients, 11 (84.6%) and 5 (38.5%) achieved PASI75 and PASI90 response, respectively. @*Conclusion@#This study showed that secukinumab improves the HRQOL of patients with PsA, implying a positive influence of secukinumab on patients’ physical and mental status in a real-world clinical setting.